60 Degrees Pharmaceuticals Inc (SXTP) Stock Price, Quote & News

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumoni...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 327 5422

Website: www.60degreespharma.com

Address:

1025 Connecticut Avenue NW, Suite 1000, Washington, United States

MASVRE Aug. 19 at 5:08 AM

$SXTP +4 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has a corporate history linked to West African infectious disease work, including a 2014 Ebola mission, though its current commercial focus is on its FDA-approved malaria prevention drug Arakoda (tafenoquine), alongside active clinical trials for tick-borne babesiosis. Look out for an ebola play here

0 · Reply

cgz147258 Aug. 16 at 2:45 PM

$SXTP

0 · Reply

Fi0na__B Aug. 16 at 4:10 AM

I'll probably take some $SXTP if it touches the $1.08-$1.10 support area for a bounce. Same with $WOK if it dips a few percent below VWAP. Wonderful setup on $IPST, 1.25M float and clean filings, could continue Friday action from ~$2.70 for another push to $5.00.

0 · Reply

MGAP Aug. 15 at 5:37 PM

$ONFO follow this guy. Accurate . Stock went up 200% Friday $SXTP $WMT $OMCL

1 · Reply

Day3 Aug. 7 at 4:50 PM

$SXTP *Knight Therapeutics have taken a 20% stake *Shareholders approved a management incentive for a minimum$40M deal value, rising if deal value is$100M+. *Recent PIPE extends cash runway through mid October to cover interim data readout for Babesiosis study. Read between the lines and you'll see there's a deal on the horizon, potentially valued at 10x their current market cap.

0 · Reply

dark_gamma Aug. 7 at 2:06 PM

$META OPTIONS LEVELS :-) Date: 2026-08-07 KEY LEVELS: Call Wall: $600.00 Put Wall: $580.00 Gamma Flip Point: $WUBA WHALE ACTIVITY: Dark Gamma Position: $590.16 Whale 1: $590.24 Whale 2: $587.94 Whale 3: $588.77 Whale 4: $590.66 Whale 5: $589.33 VOLATILITY GUIDELINES: Upper Volatility Range: 1σ $603.43 | 2σ $SXTP Lower Volatility Range: 1σ $576.37 | 2σ $56COM.P Daily Level Updates → Follow dark_gamma for latest information. Disclaimer: The information provided is for educational purposes only and should not be considered as investment advice.

0 · Reply

focafoca99 Aug. 4 at 9:03 PM

$SXTP closed a private placement of 191,571 shares and warrants at $1.74 per share, raising about $1.0 million.

1 · Reply

ChartChartist Jul. 30 at 7:42 PM

$SXTP nice offerings $PMAX bank central

0 · Reply

Hooparena Jul. 30 at 6:58 PM

$SXTP Just the luck of having multiple press releases of positive advancements of the new drug and the amazing purchase of a 20% stake by Knight and then this news hits. The offering is already spoken for (by Knight, I wonder?) so the stock is not going to be hitting the market anytime soon. Maybe that is why Knight issued the press release yesterday possibly knowing they might have spoken for the new shares and will have to make an additional filing soon. If it was Knight, they double their percentage of shares. Just my thoughts.

0 · Reply

flychicken1991 Jul. 30 at 6:42 PM

$SXTP Negative (91%): SXTP's stock price faces immediate pressure because the placement increases the number of common shares or equivalents and introduces warrants capable of creating up to 574,713 additional shares... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/db3fec30f6260068?utm_source=stocktwits&utm_medium=story_url

0 · Reply

Market Cap	2.87M
Revenue (ttm)	1.41M
Net Income (ttm)	-7.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-522.70%
Debt to Equity Ratio	0.00

Volume	36,500
Avg Vol	121,734
Day's Range	N/A - N/A
Shares Out	2.66M
Stochastic %K	42%
Beta	2.54
Analysts	Sell
Price Target	$3.70